Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.

However, in the propensity score-matched sintilimab subgroup, univariate analysis indicated only a borderline significant association (HR:1.53, 95% CI: 0.94-2.49, P = 0.088), which lost statistical significance after multivariable adjustment (HR:1.50, 95% CI: 0.92-2.45, P = 0.101).This discrepancy may be attributed to several factors: First, while propensity score matching balanced known prognostic variables, there may be unmeasured confounding variables, unmeasured confounders including tumor microenvironment heterogeneity, genomic profiles, or lifestyle differences may persist.

also in 11,409 other papers